ImmunoGen competitorsClear all

ImmunoGen's top competitors include ADC Therapeutics, Puma Biotechnology, Immunomedics and Ablynx.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
ImmunoGen
ImmunoGen
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
ADC Therapeutics
ADC Therapeutics
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Ablynx
Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
Founding Date
Founding Date
1981
Founding Date
2010
Founding Date
2010
Founding Date
1982
Founding Date
2001
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Waltham, US HQ
Locations
Epalinges, CH HQ
Greater London, GB
New Providence, US
San Mateo, US
Locations
Los Angeles, US HQ
Locations
Morris Plains, US HQ
Rödermark, DE
Locations
Gent, BE HQ
Employees
Employees
795% increase
Employees
1162% increase
Employees
27214% decrease
Employees
3666% increase
Employees
3293% decrease
Valuation ($)
Valuation ($)
788 m
Valuation ($)
540.9 m
Valuation ($)
81.8 m
Valuation ($)
20.3 b
Valuation ($)
N/A
Twitter followers
Twitter followers
1.1 k
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
583
Twitter followers
282
Alexa Website Rank
Alexa Website Rank
413660
Alexa Website Rank
281965
Alexa Website Rank
N/A
Alexa Website Rank
374918
Alexa Website Rank
N/A
Employee Rating
Employee Rating
3.4
Employee Rating
4.3
Employee Rating
3.2
Employee Rating
2.9
Employee Rating
3.3

Financial

Revenue (est.)
Revenue (est.)
$132.3m (FY, 2020)
Revenue (est.)
$33.9m (FY, 2021)
Revenue (est.)
$225.1m (FY, 2020)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
€85.2m (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
($1.3m) (FY, 2021)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$32.6m (FY, 2021)
Gross profit
N/A
Gross profit
$295k (FY, 2019)
Gross profit
N/A
Net income
Net income
($44.4m) (FY, 2020)
Net income
($230m) (FY, 2021)
Net income
($60m) (FY, 2020)
Net income
($357.3m) (FY, 2019)
Net income
(€1.1m) (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
390 (Sep, 2020)
Patents (US)
50 (Q2, 2017)

Funding

Total funding raised
Total funding raised
$ 56m
Total funding raised
$ 526m
Total funding raised
$ 172m
Total funding raised
$ 30m
Total funding raised
$ 498.8m
For sources of this data, please see the company profile

View company profiles

ADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase

ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.

View company
Puma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

View company
Immunomedics
HQ
Morris Plains, US
Employees
366↑ 6% increase

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Ablynx
HQ
Gent, BE

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.

View company